1. Netherlands Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Koninklijke Philips N.V.

Koninklijke Philips N.V.

RYLPF
Koninklijke Philips N.V.US flagOther OTC
27.58
USD
- -
- -
26.96BMarket Cap
Koninklijke Philips N.V.
RYLPF
(Other OTC)

Recent

price

27.58

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
21.51
20.01
21.76
21.9
21.2
16.64
17.22
17.37
17.81
17.23
17.65
17.56
18.72
19.15
19.31
18.81
18.54
Revenue per Share
1.39
-1.39
-0.03
1.16
0.41
0.62
1.43
1.62
1.07
1.17
1.21
3.4
-1.69
-0.49
-0.75
0.94
1.17
Basic EPS, GAAP
1.95
-0.03
1.81
0.86
1.18
0.49
1.06
1.72
1.63
1.68
2.44
1.56
-0.29
2.15
1.55
1.09
2.27
Free Cash Flow per Basic Share
0.29
0.25
0.25
0.27
0.29
0.3
0.33
0.38
0.39
0.46
- -
0.49
0.43
- -
- -
0.35
0.37
Dividend per Share
14.42
12.06
11.06
10.85
10.78
11.54
12.34
11.75
12
12.83
12.14
15.36
13.91
12.83
12.98
11.52
11.71
Book Value per Share
2.7
1.28
0.47
1.4
0.34
-0.55
0.09
0.93
- -
0.49
0.88
0.16
-0.54
-1.11
-1.47
-0.93
-0.81
Tangible Book Value per Share
1,036
1,049
1,022
1,004
1,009
1,010
1,012
1,024
1,017
995
981
977
952
949
933
948
953
Basic Weighted Avg Shares
22,287
20,992
22,234
21,990
21,391
16,806
17,421
17,780
18,121
17,147
17,312
17,156
17,827
18,169
18,021
17,834
17,665
Sales/Revenue/Turnover
9.31
4.17
2.66
8.56
2.29
3.92
8.42
7.99
9.13
8.11
8.11
3.63
-0.99
-0.92
2.85
8.12
9.89
Operating Margin (%)
1,343
1,400
1,242
1,177
1,187
972
976
1,025
1,089
1,343
1,462
1,323
1,602
1,261
1,389
1,124
1,227
Depreciation Expense
1,442
-1,460
-35
1,169
415
624
1,448
1,657
1,090
1,167
1,187
3,319
-1,608
-466
-702
895
1,114
Net Income, GAAP
25.45
- -
82.89
30.56
14.05
51.37
19.63
25.34
12.84
20.67
17.51
- -
- -
- -
782.93
23.86
24.71
Effective Tax Rate (%)
6.47
-6.96
-0.16
5.32
1.94
3.71
8.31
9.32
6.02
6.81
6.86
19.35
-9.02
-2.56
-3.9
5.02
6.31
Profit Margin (%)
3,839
3,109
2,573
2,998
3,715
2,734
3,602
3,252
1,629
2,481
3,493
2,898
2,325
1,654
1,878
2,421
1,907
Working Capital
2,818
3,278
3,725
3,309
3,712
4,095
4,021
3,468
3,238
4,876
5,590
5,737
7,017
6,959
7,048
6,811
6,316
LT Debt
15,092
12,350
11,185
11,227
10,968
11,780
13,453
12,023
12,117
12,625
11,901
14,475
13,283
12,061
12,043
10,989
11,476
Total Equity
7.92
- -
0.62
8.3
2.73
1.94
6.31
5.9
8.84
6.43
6.44
- -
- -
- -
-18.06
5.75
6.92
Return on Invested Capital (%)
8.72
- -
0.22
9.36
5.14
5.09
9.18
9.24
7.84
7.87
7.44
- -
- -
- -
-15.46
5.83
7.13
Return on Capital (%)
9.73
-10.67
-0.3
10.45
3.76
5.54
11.96
13.5
9.05
9.46
9.7
25.23
-11.62
-3.69
-5.84
7.8
10.21
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,000
1,206
1,149
LT Borrowings
6,054
6,891
6,316
LT Finance Leases
757
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
951
952
977
Market Capitalization
21,324
21,804
22,407

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,932
9,784
9,330
Cash, Cash Equivalents & STI
2,794
2,592
1,789
Accounts Receivable, Net
3,339
3,262
3,550
Inventories
2,870
3,110
3,216
Total Current Liabilities
7,511
7,432
7,423
Payables & Accruals
3,988
3,513
3,728
ST Debt
1,000
1,206
1,149
Deferred Revenue
1,490
1,617
1,584

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.19%
-0.94%
-8.75%
Free Cash Flow
-82.58%
-209.21%
-28.6%
Net Income, GAAP
-9.57%
-43.34%
-227.49%
Sales/Revenue/Turnover
0.63%
0.62%
-1.04%
Total Cash Common Dividend
8,058.07%
16,127.19%
32,700%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,138
4,462
4,377
5,044
18,021
2025
4,097
4,338
4,302
5,098
17,834
2026
3,905
4,360
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.07
0.47
0.19
-0.36
-0.75
2025
0.08
0.25
- -
0.42
0.94
2026
0.16
0.4
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
0.31
- -
- -
0.35
2026
- -
0.34
- -
- -
- -
Similar Companies
Episurf Medical AB (EPIS-B.ST)
Aurora Spine Corporation (ASG.V)
Guided Therapeutics, Inc. (GTHP)
Carmat S.A. (CKMTF)
ALR Technologies Inc. (ALRTF)
Peijia Medical Limited (9996.HK)
Business
Koninklijke Philips N.V. (Philips) is a leading health technology company that develops and manufactures diagnostic imaging systems, image-guided therapy devices, patient monitoring solutions, enterprise informatics software, sleep and respiratory care products; personal health devices including electric toothbrushes, shavers, beauty appliances, mother and childcare products; and related healthcare informatics and connected care platforms. The company operates through three main segments: Diagnosis & Treatment, which includes precision diagnostics and image-guided therapy equipment such as CT scanners, MRI systems, ultrasound devices, X-ray systems and resuscitation tools; Connected Care, encompassing monitoring equipment, sleep apnea devices, software solutions and informatics; and Personal Health, featuring grooming kits, skin care devices, breast pumps, air purifiers and baby monitors. Philips serves healthcare providers, hospitals, consumers and underserved communities globally, with key markets in North America, Europe, Asia-Pacific including Singapore and Indonesia, and the United States, generating most revenue outside its home country. Founded in 1891 and headquartered in Amsterdam, the Netherlands, with significant operations in Eindhoven, Best and Andover, Massachusetts, Philips maintains a workforce of approximately 69,700 across over 100 countries and invests around 9% of sales in R&D, focusing half on software and data science, holding over 50,500 patent rights as the top MedTech filer with the European Patent Office. The company targets value-based care in cardiology, oncology, neurology, peripheral vascular, surgery and general healthcare, aiming to improve 2.5 billion lives annually by 2030, including 400 million in underserved areas. In recent developments, Philips announces a USD 150 million investment in U.S. manufacturing and R&D, expanding facilities in Reedsville, Pennsylvania for AI-enabled ultrasound systems and Plymouth, Minnesota for image-guided therapy to support growth; secures a landmark agreement with Indonesia's Ministry of Health for Azurion systems installation in East Java; reports Q3 2025 results with 8% comparable order intake growth, 3.3% sales increase across segments, margin expansion and EUR 222 million productivity savings as part of a EUR 2.5 billion three-year program including EUR 800 million in 2025; advances a EUR 2.5 billion productivity initiative for efficiency and simplification; and receives ongoing support from investor Exor amid 19% total shareholder return in 2024.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Koninklijke Philips N.V. (PHG) Q1 2026 Earnings Call Transcript